

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

accept change(s) to the agreed paediatric investigation plan (MHRA-100288-PIP01-21-M01).  
MHRA-100288-PIP01-21-M02

### **Scope of the Application**

#### **Active Substance(s)**

DENOSUMAB

#### **Condition(s)**

Treatment of Osteoporosis

#### **Pharmaceutical Form(s)**

Solution for injection

#### **Route(s) of Administration**

SUBCUTANEOUS USE

#### **Name / Corporate name of the PIP applicant**

Amgen Limited

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, Amgen Limited submitted to the licensing authority on 31/03/2023 16:16 BST an application for a Modification

The procedure started on 12/07/2023 15:06 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-100288-PIP01-21-M02

Of 17/08/2023 13:39 BST

On the adopted decision for DENOSUMAB (MHRA-100288-PIP01-21-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan

This decision applies to a Modification for DENOSUMAB, Solution for injection , SUBCUTANEOUS USE .

This decision is addressed to Amgen Limited, 216 Cambridge Science Park, Milton Road, Cambridge, UNITED KINGDOM, CB4 0WA

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of osteoporosis The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 2 years of age. Pharmaceutical form(s): Solution for injection Route(s) of administration: SUBCUTANEOUS USE Reason for granting waiver: on the grounds that the specific medicinal product is likely to be unsafe.

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of osteoporosis.

#### 2.2 Indication(s) targeted by the PIP:

Treatment of osteogenesis imperfecta. Treatment of glucocorticoid induced osteoporosis in paediatric patients who had previously experienced an osteoporotic fracture.

### 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 2 years to less than 18 years of age.

### 2.4 Pharmaceutical Form(s):

Solution for injection.

### 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not applicable.
Non-Clinical Studies	0	Not applicable.
Clinical Studies	2	Study 1 (Osteogenesis imperfecta study) Open-label single-arm, historically controlled study to evaluate safety, efficacy and pharmacokinetics of denosumab in children from 2 to less than 18 years of age with osteogenesis imperfecta. Study 2 (GIOP study) Double-blind, placebo-controlled randomised study to evaluate safety and efficacy of denosumab in children from 5 to less than 18 years of age with glucocorticoid-induced osteoporosis.
Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/12/2023
Deferral of one or more studies contained in the paediatric investigation plan:	Yes

